WWQ-03-012

Overview

WWQ-03-012 is a selective deSUMOylating isopeptidases DESI2 inhibitor with an IC 50 of 47.3 μM. WWQ-03-012 cans induce JAK2-V617F ubiquitination-proteasome degradation with no significant effect on wild-type JAK2 . WWQ-03-012 can block JAK2-STAT3/5 signaling, inhibit cell proliferation and induce apoptosis . WWQ-03-012 has a synergistic effect in combination with Ruxolitinib ( HY-50856 ), further enhancing its killing effect on JAK2 mutant cells. WWQ-03-012 can be used for the research of cancer , such as myeloproliferative neoplasms.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > JAK/STAT Signaling | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > STAT | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Deubiquitinase | Products > Signaling Pathways > JAK

Product Information

• Catalog No.: HY-180561
• CAS No.: 3076807-15-0
• Molecular Formula: C20H16N4O3S
• Molecular Weight: 392.43
• Purity: 98.04%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (6.37 mM); Clear solution
• Availability: In-stock

Source

Original product source